Acupuncture: A Promising Approach for Comorbid Depression and Insomnia in Perimenopause

Perimenopause represents a critical period in women's lives, characterized by significant hormonal changes that often result in debilitating symptoms such as depression and insomnia. This comprehensive review examined the available evidence on the use of acupuncture for the treatment of these comorbid symptoms, analyzing both clinical and preclinical studies. The authors conducted a systematic analysis of 47 randomized controlled trials, involving more than 4,200 participants, in addition to multiple animal model studies. The results demonstrate that acupuncture offers significant benefits in the treatment of perimenopausal depression and insomnia.

When compared with placebo or wait-list controls, acupuncture showed consistent improvements in sleep quality and depressive symptoms. In direct comparisons with conventional medications, including antidepressants such as fluoxetine and hypnotics such as estazolam, acupuncture demonstrated equivalent or superior efficacy. The meta-analysis revealed a mean reduction of 2.24 points on the Pittsburgh Sleep Quality Index and 0.54 standard deviations on the Hamilton Depression Scale. A particularly notable aspect was the exceptional safety profile of acupuncture.

While conventional medications had adverse event rates as high as 29.4% (including daytime sleepiness, breast tenderness, and sleep disturbances), acupuncture showed only mild adverse events in less than 8% of cases, mainly local hematomas that resolved spontaneously within a few days. The studies also indicated that acupuncture offers holistic benefits, improving not only sleep and mood but also other climacteric symptoms such as hot flashes, quality of life, and anxiety. This integral approach is consistent with the principles of Traditional Chinese Medicine, which views the body as an integrated system. The most frequently used acupoints were Sanyinjiao (SP-6) for gynecologic disorders, Baihui (GV-20) for psychiatric disorders, Shenmen (HT-7) for sleep promotion, and Yintang (EX-HN3) for emotional issues.

From a mechanistic standpoint, animal model studies revealed that acupuncture acts through multiple pathways: modulation of reproductive hormones (increasing estradiol and reducing follicle-stimulating and luteinizing hormones), regulation of neurotransmitters (GABA and serotonin), inhibition of hyperactivity of the hypothalamic-pituitary-adrenal and hypothalamic-pituitary-ovarian axes, and reduction of oxidative stress. These findings provide a solid scientific basis for the effects observed clinically. The review also identified important limitations in the existing studies. Many trials had methodologic shortcomings, including inadequate sample sizes, lack of appropriate blinding, absence of intention-to-treat analyses, and insufficient follow-up periods.

In addition, all studies were conducted in China, limiting generalization of the results to other populations. For clinical practice, the authors suggest that acupuncture can be considered as a first-line treatment for perimenopausal women with depression and insomnia, particularly for those who prefer to avoid medications or are intolerant to them. Combined therapy (acupuncture plus reduced-dose medications) also showed promise for more complex cases. The findings have important implications for the care of midlife women, offering an evidence-based alternative that can significantly improve quality of life during this challenging transition.